Skip to content
Cultural Foundation
Author:
Lungpacer Medical USA Inc.
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
July 28, 2026
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
July 22, 2026
Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
June 23, 2026
Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer
June 1, 2026